DS 8895

Drug Profile

DS 8895

Alternative Names: DS-8895a

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (IV) (Daiichi Sankyo pipeline, May 2017)
  • 01 Feb 2017 Daiichi Sankyo completes a phase I trial in Solid tumours (Late-stage disease) in Japan (IV) (NCT02004717)
  • 16 Mar 2016 Phase-I development is ongoing in Australia and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top